Work

Data Supplement from Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

Year: 2023

Type: other

Abstract: Supplementary Table S1. Patient characteristics genotyped cohort vs non-genotyped cohort. Supplementary Table S2. Patient characteristics according to FCGR3A genotype. Supplementary Table S3. Patient characteristics according to FCGR2A genotype. Supplementary Table S4. Patient characteristics according to FCGR2B genotype. Supplementary Figure S1. DFS was not improved for any genotypic group in the trastuzumab-containing regimens.

DOI: 10.1158/2326-6066.22536017.v1

Authors: Nadine Norton, Rebecca M. Olson, Mark Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362628172

Cites:

Cited by:

Related to: 10